Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

3E Bioventures

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 38
Average round size
info
The average size of a deal this fund participated in
$34M
Portfolio companies 27
Rounds per year 4.75
Lead investments 9
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.26
Exits 1
Key employees 2

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Medical Device
  • Biopharma
Summary

The venture was found in Asia in China. The main department of described VC is located in the Beijing.

Among the most successful fund investment fields, there are Genetics, Clinical Trials. Among the most popular portfolio startups of the fund, we may highlight Ansun BioPharma, Profusa, Apexigen. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the 3E Bioventures, startups are often financed by SDIC Venture Capital, BioVeda China Fund, Morningside Group. The meaningful sponsors for the fund in investment in the same round are CMB International Capital Corporation, WuXi Healthcare Ventures, Shangbay Capital. In the next rounds fund is usually obtained by WuXi Healthcare Ventures, VT Ventures, Tasly Pharmaceutical.

Speaking about the real fund results, this VC is 9 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2018. The fund is constantly included in 2-6 deals per year. The common things for fund are deals in the range of 10 - 50 millions dollars.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of 3E Bioventures:
Typical Co-investors
3E Bioventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after 3E Bioventures:
There are no funds here. If we find new data, we will add it here.

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Junhemeng Biopharmaceutical

Biopharma
Biotechnology
Medical
$13M16 Jan 2023 Hangzhou, Zhejiang, China

Subtle Medical

Artificial Intelligence
Health Care
Health Diagnostics
Machine Learning
Medical
Software
$25M17 Nov 2022 California, United States

Regenacy Pharmaceuticals

Biotechnology
Medical
Therapeutics
$9M15 Aug 2022 Massachusetts, United States

CytoNiche

Biotechnology
Health Care
$46M03 Mar 2022 Dongcheng District, Beijing, China

Dermaliq Therapeutics

Fitness
Health Care
Pharmaceutical
Wellness
$15M18 Jan 2022 Wilmington, Delaware, United States

Zhengli Technology

Dental
Health Care
Manufacturing
Medical
Medical Device
29 Dec 2021 Guangdong, Tianjin, China

Boaoxin

Biopharma
Biotechnology
Medical
Medical Device
$30M09 Dec 2021 Nanjing, Jiangsu, China

ITabMed

Biopharma
Biotechnology
Health Care
Therapeutics
$20M01 Dec 2021 Shanghai, Shanghai, China

Novlead Biotech

Biotechnology
Medical
Pharmaceutical
$18M16 Nov 2021 Nanjing, Jiangsu, China
News
Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel E3 Ligands Platform

– Cullgen Inc. closed a $50m Series B financing (assuming exercise of warrant).
– The round was led by 3E Bioventures Capital, as well as Heights Capital Management (an affiliate of Susquehanna International Group), Octagon Capital, MSA Capital and South China Venture Capital.
– The financing will support the development of Cullgen’s technology platform and internal pipeline of targeted protein degraders in oncology and other diseases.
– Frank Yan, from 3E Bioventures, will be joining Cullgen’s board of directors.
– Cullgen is also pleased to announce that Frank Yan, from 3E Bioventures, will be joining Cullgen’s board of directors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent 3E Bioventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: